IPSEN (OTCMKTS:IPSEY) Shares Down 8.3% – Here’s Why

IPSEN (OTCMKTS:IPSEY)’s stock price fell 8.3% on Monday . The company traded as low as $42.4080 and last traded at $42.4080. Approximately 241 shares traded hands during trading, a decline of 87% from the average session volume of 1,899 shares. The stock had previously closed at $46.2280.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a report on Tuesday, June 30th. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

IPSEN Price Performance

The stock’s fifty day moving average is $46.34 and its two-hundred day moving average is $46.70.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.